English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  The Case for Proteomics and Phospho-Proteomics in Personalized Cancer Medicine

Doll, S., Gnad, F., & Mann, M. (2019). The Case for Proteomics and Phospho-Proteomics in Personalized Cancer Medicine. PROTEOMICS - Clinical Applications, 13(2, SI): 1800113. doi:10.1002/prca.201800113.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/21.11116/0000-0003-E164-E Version Permalink: http://hdl.handle.net/21.11116/0000-0003-E169-9
Genre: Journal Article

Files

show Files
hide Files
:
Doll_et_al-2019-PROTEOMICS_-_Clinical_Applications.pdf (Publisher version), 636KB
Name:
Doll_et_al-2019-PROTEOMICS_-_Clinical_Applications.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
© 2019 The Authors.

Locators

show

Creators

show
hide
 Creators:
Doll, Sophia1, Author              
Gnad, Florian1, Author              
Mann, Matthias1, Author              
Affiliations:
1Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565159              

Content

show
hide
Free keywords: BIOMARKER DISCOVERY; MASS-SPECTROMETRY; PROTEOGENOMIC CHARACTERIZATION; CLINICAL-RESPONSE; HIGH-RESOLUTION; OVARIAN-CANCER; LUNG-CANCER; MUTATIONS; TISSUE; HETEROGENEITYBiochemistry & Molecular Biology; mass spectrometry; clinical proteomics; oncology;
 Abstract: The concept of personalized medicine is predominantly been pursued through genomic and transcriptomic technologies, leading to the identification of multiple mutations in a large variety of cancers. However, it has proven challenging to distinguish driver and passenger mutations and to deal with tumor heterogeneity and resistant clonal populations. More generally, these heterogeneous mutation patterns do not in themselves predict the tumor phenotype. Analysis of the expressed proteins in a tumor and their modification states reveals if and how these mutations are translated to the functional level. It is already known that proteomic changes including posttranslational modifications are crucial drivers of oncogenesis, but proteomics technology has only recently become comparable in depth and accuracy to RNAseq. These advances also allow the rapid and highly sensitive analysis of formalin-fixed and paraffin-embedded biobank tissues, on both the proteome and phosphoproteome levels. In this perspective, pioneering mass spectrometry-based proteomic studies are highlighted that pave the way toward clinical implementation. It is argued that proteomics and phosphoproteomics could provide the missing link to make omics analysis actionable in the clinic.

Details

show
hide
Language(s): eng - English
 Dates: 2019
 Publication Status: Published online
 Pages: 10
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: ISI: 000462774400001
DOI: 10.1002/prca.201800113
 Degree: -

Event

show

Legal Case

show

Project information

show hide
Project name : Max Planck Society for the Advancement of Science and the Novo Nordisk Foundation. Grant Number: NNF15CC0001
Grant ID : NNF15CC0001
Funding program : -
Funding organization : Novo Nordisk Foundation

Source 1

show
hide
Title: PROTEOMICS - Clinical Applications
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: POSTFACH 101161, 69451 WEINHEIM, GERMANY : WILEY-V C H VERLAG GMBH
Pages: - Volume / Issue: 13 (2, SI) Sequence Number: 1800113 Start / End Page: - Identifier: ISSN: 1862-8346